This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AEterna Zentaris, Inc.
Drug Names(s): AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108
Description: AEZS-108 is a cytotoxic peptide hormone conjugatebased on luteinizing hormone-releasing hormone (LHRH) in which doxorubicin (DOX) or 2-pyrrolino-DOX respectively is linked to [D-Lys6]LHRH show high-affinity binding to the LHRH receptor,providing a selective target through receptor-mediated internalization.
Aeterna and Ventana
In January 2012, Aeterna Zentaris announced it entered into a collaboration agreement with Ventana Medical Systems, a member of the Roche Group, to develop a companion diagnostic for the immunohistochemical determination of luteinizing hormone-releasing hormone (LHRH) receptor expression.
Aeterna and Ergomed
In April 2013, Aeterna Zentaris announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase III trial with AEZS-108 in endometrial cancer.
Under the terms of the agreement, Ergomed will assume 30% (up to $10 million) of the clinical and regulatory costs for the Phase III trial with AEZS-108 in endometrial cancer, which are estimated at approximately $30 million over the course of the study. Ergomed will receive its...See full deal structure in Biomedtracker
Partners: Ergomed PLC Sinopharm Group Company Limited Orient Europharma Co., Ltd. Rafa Laboratories, Ltd. Specialised Therapeutics Asia Pte Ltd
Additional information available to subscribers only: